Garcinol exhibits anti-inflammatory and anticancer activities; it inhibits acetylcholinesterase (AChE, IC50 = 0.66 µM) and butyrylcholinesterase (BChE, IC50 = 7.39 µM); it suppresses histone acetyltransferases (HATs, IC50 = 7 µM) and p300/CBP-associated factor (PCAF, IC50 = 5 µM); it inhibits proliferation and induces apoptosis in head and neck squamous cell carcinoma (HNSCC) cell lines (CAL27 and UMSCC1) in a time- and dose-dependent manner; it suppresses phosphorylation and degradation of constitutive IκBα in a time-dependent manner; it significantly inhibits tumor growth in vivo in a CAL27 xenograft mouse model.